

Advising claimant on resorting to the DIFC courts to obtain Mareva injunctions as part of a global recovery strategy.

January 17, 2026

Advising claimant on resorting to the DIFC courts to obtain Mareva injunctions as part of a global recovery strategy.

Advising a large holding company on defending against injunctions filed in London, New York, and the UAE simultaneously.

January 17, 2026

Advising a large holding company on defending against injunctions filed in London, New York, and the UAE simultaneously.

Representation in a USD 40M vicarious liability dispute in the UAE courts between a UAE major retailer and a Korean MNC.

January 17, 2026

Representation in a USD 40M vicarious liability dispute in the UAE courts between a UAE major retailer and a Korean MNC.

Representation in a USD 120M dispute between an HNW individual and a major bank related to the illegitimate use of financial instruments.

January 17, 2026

Representation in a USD 120M dispute between an HNW individual and a major bank related to the illegitimate use of financial instruments.

Representation in a USD 20M shareholder dispute between an exiting shareholder and a global engineering firm regarding valuation.

January 17, 2026

Representation in a USD 20M shareholder dispute between an exiting shareholder and a global engineering firm regarding valuation.

Representation in a USD 120M derivative shareholder claim for a Canadian shareholder arising from allegations of corporate fraud.

January 17, 2026

Representation in a USD 120M derivative shareholder claim for a Canadian shareholder arising from allegations of corporate fraud.

Representing a shareholder of a Fin-Tech firm in pursuing allegations of breach of governance and fiduciary duties.

January 17, 2026

Representing a shareholder of a Fin-Tech firm in pursuing allegations of breach of governance and fiduciary duties.

Representation in a USD 60M capital markets dispute between a shareholder of a listed firm and a block trade acquirer.

January 17, 2026

Representation in a USD 60M capital markets dispute between a shareholder of a listed firm and a block trade acquirer.

Representation in a USD 40M dispute between an institutional investor and a pharmaceutical firm for misrepresentation of assets.

January 17, 2026

Representation in a USD 40M dispute between an institutional investor and a pharmaceutical firm for misrepresentation of assets.